id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-350373-dftdxzsm	Rayman, G.	Dexamethasone therapy in COVID‐19 patients: implications and guidance for the management of blood glucose in people with and without diabetes	2020-08-02		.txt	text/plain	1745	94	56	title: Dexamethasone therapy in COVID‐19 patients: implications and guidance for the management of blood glucose in people with and without diabetes The guidance recommends giving correction doses of rapid-acting analogue insulin when capillary blood glucose > 12.0 mmol/l, with the dose calculated according to the patient's weight or in those already treated with insulin, on their total daily insulin dose. Unlike the previous guidance, we do not recommend using the insulin correction ratios that some people with type 1 diabetes usually use as these may not be appropriate given the significant disturbance of glucose metabolism. Insulin resistance will fall when dexamethasone is stopped and so capillary blood glucose and insulin dose adjustment need careful monitoring to avoid hypoglycaemia. Where the total daily dose (TDD) of insulin is known follow the guidance in the Increase the long acting basal or NPH insulin by 20% but this may need rapid escalation by as much as 40% depending on response.	./cache/cord-350373-dftdxzsm.txt	./txt/cord-350373-dftdxzsm.txt